Largest study of its kind finds common lab tests aren’t reliable for diagnosing Long COVID

A new study found that most routine laboratory tests are not reliable for diagnosing Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC).

The study, published today in Annals of Internal Medicine, found no reliable biomarker among 25 routine clinical laboratory values for prior infection, PASC or specific types of PASC clusters. This suggests none of these routine labs can serve as a clinically useful biomarker of PASC.

“Our study shows patients can have severe Long COVID with normal lab results. This suggests doctors should not focus on the results of blood panels to diagnose Long COVID but should focus more on symptoms and ways to help patients get relief by treating their symptoms,” said the study’s first author, Kristine Erlandson, MD, a professor in the Division of Infectious Diseases at the University of Colorado Anschutz Medical Campus.

Seven percents of all adults in the U.S., nearly 18 million people, currently have long COVID, according to Agency for Healthcare Research and Quality’s Medical Expenditure Panel Survey.

“Our challenge is to discover biomarkers that can help us quickly and accurately diagnose long COVID to ensure people struggling with this disease receive the most appropriate care as soon as possible,” said David Goff, MD, PhD, director for the Division of Cardiovascular Sciences at the NIH’s National Heart, Lung, and Blood Institute. “Long COVID symptoms can prevent someone from returning to work or school, and may even make everyday tasks a burden, so the ability for rapid diagnosis is key.”

This study was funded by National Institutes of Health’s (NIH) Researching COVID to Enhance Recovery (RECOVER) Initiative. The RECOVER initiative includes multiple research studies that involve thousands of participants from across the country. In Colorado, these studies take place in the Colorado Clinical and Translational Sciences Institute (CCTSI) at CU Anschutz.

To investigate clinical laboratory markers of SARS-CoV-2 and PASC, the researchers examined data from nearly 10,000 adults with and without SARS-CoV-2 infection. The researchers recruited from over 80 enrolling sites across 33 U.S. states plus Washington, DC and Puerto Rico, making it one of the largest and most diverse studies of its kind.

The study compared results in several ways: between participants with and without prior SARS-CoV-2 infection at six months after infection, between participants with and without PASC and between participants with each of four most common PASC symptom phenotypes and those unlikely to have PASC.

They found participants with prior SARS-CoV-2 infection showed modest increases in HbA1c (a marker of long-term blood sugar levels) and urinary albumin-to-creatinine ratio (uACR), along with small decreases in platelet counts.

“While these differences are statistically significant, these associations are generally small and not reliable enough to serve as diagnostic biomarkers for PASC,” Erlandson says.

The researchers suggest this data shows the complexity of PASC as a condition that may involve multiple physiological pathways beyond simple laboratory markers, such as those for inflammation, anemia or other markers.

“Long COVID has been very elusive; numerous possible symptoms, no definite cause and no clear treatment. We hear from patients that their concerns are dismissed by providers because their lab tests are normal. In this study, even the exhaustive list of routine blood tests could not help in making a PASC diagnosis. This is an important observation in PASC research as prior smaller studies showed inconsistent abnormalities in some blood tests. Until a reliable biomarker is found, the best diagnostic modality for PASC remains the old-fashioned history taking and clinical assessment,” Grace McComsey, MD, senior author of the paper, professor and vice dean of clinical and translational research at Case Western Reserve University.

The researchers also note that it’s still important to do routine laboratory tests to rule out other conditions during the process of diagnosing PASC.

About the University of Colorado Anschutz Medical Campus

The University of Colorado Anschutz Medical Campus is a world-class medical destination at the forefront of transformative science, medicine, education and patient care. The campus encompasses the University of Colorado health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals – UCHealth University of Colorado Hospital and Children’s Hospital Colorado – which see more than 2 million adult and pediatric patient visits yearly. Innovative, interconnected and highly collaborative, the University of Colorado Anschutz Medical Campus delivers life-changing treatments, patient care and professional training and conducts world-renowned research fueled by $705 million in research grants. For more information, visit www.cuanschutz.edu.